Sort   by:  
 Page size 
UnknownImpact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

Purpose

The impact of a personalized cancer treatment strategy (ie, matching patients with drugs based on specific biomarkers) is still a matter of debate.

Methods

We reviewed phase II single-agent studies (570 studies; 32,149 patients) published between January 1, 2010, and December ...
S-EPMC4737863 | biostudies-literature
UnknownInitiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.
Genomic profiling is increasingly used in the management of cancer. We have previously reported preliminary results of our precision medicine program. Here, we present response and survival outcomes for 637 additional patients who were referred for phase I trials and were treated with matched target...
S-EPMC5659750 | biostudies-literature
UnknownPhase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

Purpose

The primary objective was to determine safety, toxicity, and a recommended phase II dose regimen of LY2606368, an inhibitor of checkpoint kinase 1, as monotherapy.

Patients and methods

This phase I, nonrandomized, open-label, dose-escalation trial used a 3 + 3 dose-escalation ...
S-EPMC5321045 | biostudies-literature
UnknownCombined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Purpose

To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a selective MEK inhibitor, in patients with BRAF V600-mutant metastatic colorectal cancer (mCRC).

Patients and methods

A total of 43 patients with BRAF V600-mutant mCRC were treated with dabrafenib (...
S-EPMC4669588 | biostudies-literature
Sort   by:  
 Page size